
ULTRA-EARLY DIFFUSE LUNG DISEASE IN AN INFANT WITH PATHOGENIC VARIANT IN TELOMERASE REVERSE TRANSCRIPTASE (TERT) GENE Visekruna J, Basa M, Grba T, Andjelkovic M, Pavlovic S, Nathan N, Sovtic A *Corresponding Author: Ass. Prof. Aleksandar Sovtic, Department of Pulmonology, Mother and Child
Health Institute of Serbia, Belgrade, Serbia, School of Medicine, University of Belgrade, Serbia;
Email: aleksandar.sovtic@med.bg.ac.rs; Address: 6 Radoja Dakica, 11070 Belgrade, Serbia; Phone: +381 11 3108 158 page: 59 download article in pdf format
|
Abstract
The pathogenic variants in the telomerase reverse
transcriptase (TERT) gene have been identified in adults
with idiopathic pulmonary fibrosis, while their connec-
tion to childhood diffuse lung disease has not yet been
described. Within this study, we present a case of a five-
month-old, previously healthy infant, with early-onset
respiratory failure. The clinical suspicion of diffuse lung
disease triggered by cytomegalovirus (CMV) pneumoni-
tis was based on clinical and radiological presentation.
Multiorgan involvement was not confirmed. Considering
the possible connection between CMV pneumonitis and
early-onset respiratory failure, clinical exome sequencing
was performed and a novel variant, classified as likely
pathogenic in the TERT gene (c.280A>T, p.Lys94Ter)
was detected. After segregation analysis yielded negative
results, the de novo status of the variant was confirmed.
Respiratory support, antiviral and anti-inflammatory thera-
py offered modest benefits, nevertheless, eighteen months
after the initial presentation of disease, an unfavourable
outcome occurred. In conclusion, severe viral pneumonia has the potential to induce extremely rare early-onset
diffuse lung disease accompanied by chronic respiratory
insufficiency. This is linked to pathogenic variants in the
TERT gene. Our comprehensive presentation of the patient
contributes to valuable insights into the intricate interplay
of genetic factors, clinical presentations, and therapeutic
outcomes in cases of early-onset respiratory failure.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|